Ascendis Pharma A/S (ASND) Stock Forecast
ASND analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.76 / 5 from 21 analysts
- Price target
- $306.87 average of analyst targets
- Upside to target
- +36.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $1.14
- 52-week range
- $196.01 – $277.18
ASND analyst ratings
21 analystsNumber of analysts at each rating.
ASND price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ASND earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.94 | $0.64 | $1.09 | — | — | 3 |
| Current fiscal year (2026) | $12.79 | $3.61 | $18.69 | −$3.76 | +217.5% | 5 |
| Next fiscal year (2027) | $9.62 | $6.26 | $16.16 | $12.79 | −24.8% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ASND revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $367.2M | $352.4M | $405.3M | +71.9% | 17 |
| Current fiscal year (2026) | $1.37B | $1.33B | $1.51B | +90.8% | 19 |
| Next fiscal year (2027) | $2.02B | $1.89B | $2.30B | +46.9% | 19 |
ASND EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ASND revenue: reported and forecast
ASND EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.20 | $1.32 | $0.95 | $0.95 | $0.94 | −21.6% | 0 up · 1 down |
| Current fiscal year (2026) | $12.02 | $11.73 | $11.34 | $12.77 | $12.79 | +6.4% | 1 up · 1 down |
| Next fiscal year (2027) | $9.16 | $9.29 | $8.16 | $9.67 | $9.62 | +5.0% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ASND earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ASND beat in 4 of 12.
What analysts expect from ASND
21 analysts cover Ascendis Pharma A/S; their consensus rating is strong buy (4.76 on a 1–5 scale, where 5 is a strong buy). The average price target is $306.87, 36.2% above the latest close of $225.25. Analysts expect earnings of $12.79 per share for 2026, +217.5% from a year earlier. For 2027 the average estimate is $9.62 per share on revenue of $2.0 billion. Ascendis Pharma A/S beat the EPS estimate in 4 of the last 12 quarters.
Related: ASND income statement, ASND key metrics, ASND chart. See the ASND stock overview for the latest quote and news.
ASND forecast FAQ
What is Ascendis Pharma A/S's price target?
The average analyst price target for Ascendis Pharma A/S is $306.87, 36.2% above the latest close of $225.25.
Is Ascendis Pharma A/S a buy, hold or sell?
Of 21 analysts covering Ascendis Pharma A/S, 16 rate it a strong buy, 5 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Ascendis Pharma A/S's EPS forecast?
Analysts forecast $12.79 per share for 2026 (range $3.61 to $18.69); for 2027 the estimate is $9.62.
What is Ascendis Pharma A/S's revenue forecast?
The average revenue estimate for 2026 is $1.4 billion, growth of 90.8%; for 2027 it is $2.0 billion.
When does Ascendis Pharma A/S report earnings?
Ascendis Pharma A/S is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $1.14.
Does Ascendis Pharma A/S usually beat earnings estimates?
Ascendis Pharma A/S reported EPS at or above the analyst estimate in 4 of the last 12 quarters.